107 results about "Peptide complex" patented technology

The invention relates to the technical field of food, in particular to geobacillus stearothermophilus cKM-Geo, application of the geobacillus stearothermophilus cKM-Geo, a shrimp shell oligosaccharide peptide compound and a preparation method of the shrimp shell oligosaccharide peptide compound. The invention provides geobacillus stearothermophilus cKM-Geo, the strain can grow in an oxygen-free environment, ventilation is not needed in the process, and proteolytic enzyme, cellulase, lipase and chitin deacetylase can be highly secreted and expressed; the invention further provides a preparation method for preparing the shrimp shell oligosaccharide peptide by utilizing geobacillus stearothermophilus cKM-Geo fermentation coupling steam explosion treatment, chitin and protein in the shrimp shell are converted into water-soluble oligopeptide and oligosaccharides, the water-soluble oligopeptide and oligosaccharides are separated from calcium carbonate in the shrimp shell, acid and alkali do not need to be used, in the process, waste water is little, pollution is little, and the method is suitable for industrial production. The resource utilization rate is high.

The invention relates in one aspect to a computer-implemented method for predicting the binding of at least one protein of interest, preferably at least one receptor, antibody, antibody fragment or equivalents thereof, or DARPin, to a peptide of interest, comprising a. providing sequence and / or structural data of at least one reference peptide, optionally providing sequence and / or structural data of at least one HLA molecule and / or of at least one HLA-peptide complex (pHLA), and / or the at least one reference peptide presented within a pHLA complex, b. providing binding data, preferably comprising the dissociation constant (KD), of the at least one reference peptide and / or the at least one reference peptide presented within a HLA-peptide complex (pHLA) with at least one protein of interest, c. training a machine learning (ML)-based model or artificial intelligence (AI) based on the data provided in a. and the binding data provided in b., d. providing sequence and / or structural data of at least one peptide of interest, e. employing the machine learning (ML)- based model or artificial intelligence (AI) trained in c. to predict the binding or interaction properties of the at least one peptide of interest, preferably when presented within a pHLA complex, to the at least one protein of interest.

Methods of analyzing the presence or absence of immune cells capable of binding to an antigen peptide in a sample from one or more individuals are provided. Also provided are methods of detecting or treating cancer or a tumor, a pathogen infection, or an autoimmune disease. A display moiety is provided having particles associated with a plurality of MHC-peptide complexes, where at least two MHC-peptide complexes are different. Also provided are bait compositions having a plurality of display portions and methods of analyzing immune cells by using the display portions or bait compositions as screening tools.

This peptide includes an amino acid sequence represented by formula A1 or an amino acid sequence in which one or more amino acid residues in the amino acid sequence represented by formula A1 have been substituted, deleted, added, or inserted. A1: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14-X15

This invention discloses a histone-derived peptide nanoparticle targeting the degradation of cytoplasmic cGAS, its preparation method, and its applications. The invention is characterized by: dissolving a peptide complex in phosphate buffer, sonicating, allowing it to self-assemble at room temperature to form nanoparticles, and purifying by centrifugation to obtain histone-derived peptide nanoparticles A4@CMA NPs targeting the degradation of cytoplasmic cGAS. These nanoparticles (A4@CMA NPs) can target and bind to cytoplasmic cGAS, mediating its degradation, blocking the activation of the cGAS-STING pathway, effectively reducing periodontal inflammation and alveolar bone resorption, and providing a new strategy for the treatment of periodontitis.

The present disclosure provides T cell receptors (TCRs) against peptide-MHC complexes, isolated nucleic acid molecules encoding TCRs against peptide-MHC complexes, T cells expressing TCRs against peptide-MHC complexes, and pharmaceutical compositions for use in the treatment of HPV associated disease or cancer.

The present invention relates to a heterotandem acyclic peptide complex comprising a first peptide ligand that binds to a component present on an immune cell, which is conjugated via a linker to a second peptide ligand that binds to a component present on a cancer cell. The present invention also relates to the use of said heterotandem acyclic peptide complex in preventing, inhibiting, or treating cancer.

The present application relates to a preparation method of sea cucumber egg-derived peptide complex and application thereof.The preparation method of sea cucumber egg-derived peptide complex comprises the following steps: sea cucumber egg powder is subjected to synchronous enzymolysis by using alkaline protease and trypsin.Further separation is carried out through ultrafiltration, dextran gel chromatography and high performance liquid chromatography, sea cucumber egg-derived active peptides are obtained by using liquid chromatography-mass spectrometry technology, computer-aided screening technology and in-vitro verification, and the amino acid sequence of the sea cucumber egg-derived active peptides comprises one or several of WGN, WIGG and GFPVG.The sea cucumber egg-derived peptide complex and the sea cucumber egg-derived active peptides provided by the present application both have double activities of antioxidant and tyrosinase inhibition, can reduce melanin content, and have the advantages of good water solubility, good safety and the like.

The invention belongs to the technical field of cosmetics, and particularly relates to an anti-aging cell metabolism accelerating cosmetic and a preparation method thereof, and the technical scheme is that the anti-aging cell metabolism accelerating cosmetic comprises the following components: 0.0001%-0.005% of a cell growth factor compound, 0.0001%-0.003% of a small molecule peptide compound, 0.1%-5% of a plant stem cell extract, 1%-10% of grease, and the balance of water. 1%-10% of a surfactant, 1%-15% of a humectant, 0.1%-1% of an antioxidant, 0.1%-3% of a pH regulator, 0.05%-0.2% of a preservative and the balance of deionized water; epidermal and dermal layer cell proliferation is promoted through the cell growth factor, cell metabolism is regulated and controlled and collagen synthesis is promoted through the small molecule peptide, the plant stem cell extract is rich in polyphenol active ingredients and can activate the activity of skin endogenous stem cells, and the three components have a synergistic effect through different action pathways; the metabolism rate of skin cells and the anti-aging effect are obviously improved.

Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.

The application provides a simple and efficient TCR-mimic antibody preparation method, and a TCR-mimic antibody for gp100 / HLA-A2 is obtained by screening by using the method. The TCR-mimic antibody provided by the application can recognize a MHC-tumor antigen peptide complex with high specificity and high affinity, and has the potential to be developed as a tumor antibody drug.

The present invention relates to binding molecules comprising a T-cell receptor (TCR) variable domain capable of binding to a PIWIL1 peptide-HLA complex. The present invention also relates to the use of such molecules for the treatment of malignant diseases.

The invention discloses a CD3 antibody-polypeptide, which is characterized in that an amino acid sequence of a light chain variable region of a CD3 antibody is linked with an amino acid sequence of polypeptide through a triple link of a GGGGS flexible joint; and the CD3 antibody-polypeptide can be coupled with the RNP compound through a chemical bond to form the CD3 antibody-polypeptide-RNP compound. The CD3 antibody-polypeptide-RNP compound is used as a delivery system for gene editing in the TILs cells, in the gene editing process, CD3 antibody-polypeptide has good cell penetrability and stability, an exogenous gene can be efficiently and accurately delivered into a double-chain incision manufactured on a TRAC gene of the TILs cells, cell damage caused by electrotransfection is avoided, and the CD3 antibody-polypeptide-RNP compound can be applied to gene editing of the TILs cells. The prepared TI Ls cells have a higher proportion of memory T cells (CD45RO < + > CD62L < + >) and a higher proportion of tumor specific T cells (CD8 < + >), so that the TI Ls cells have a better tumor killing effect.

The invention relates to a preparation method and application of a narrow gadus bone active peptide compound. The preparation method of the narrow gadus bone active peptide compound comprises the following steps: carrying out primary enzymolysis on narrow gadus bone meal by using flavourzyme, separating through ultrafiltration, selecting components with molecular weight less than 3 kDa, and carrying out targeted enzymolysis by using trypsin. Further analyzing and screening the narrow gadus bone active peptide compound to obtain four kinds of narrow gadus bone active peptides, and the amino acid sequences of the four kinds of narrow gadus bone active peptides are FDY, DLGF, DGWR and ECMFPK respectively. The narrow gadus bone active peptide compound and the narrow gadus bone active peptide both have the biological activity of improving insulin resistance and reducing postprandial blood sugar, have the advantages of being good in water solubility, high in safety and the like, and can be applied to the fields of dietary nutrition, biological medicine products and the like.

A workflow is presented herein which includes methods and computational systems and devices for providing 3D computational models of potential off-target peptides each positioned in a groove of an MHC molecule ("MHC-off-target models"), quantifying structural similarity between each potential off-target peptide to a target peptide based on a comparison of the MHC-off-target models to a 3D computational model of a target MHC-peptide complex ("MHC-target model"), and ranking the potential off-target peptides based on a structural similarity metric. Example methods and systems can be applied to solve bioinformatics and treatment development problems. The present disclosure also relates to compositions that involve isolated peptides, e.g., MAGEA3168-176 and / or WT1126-134 off-target peptides, and the use of such compositions in methods for assessing off-target effects of antigen-recognition molecules that target a MAGEA3168-176 and / or WT1126-134 peptide, as well as for selecting antigen-recognition molecules and enriching samples for antigen-recognition molecules that specifically bind the MAGEA3168-176 and / or WT1126-134.

The invention relates to the technical field of medicines, in particular to a zinc ion polypeptide compound immunologic adjuvant as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing polypeptide, a PBS buffer solution, new coronavirus S protein, a CpG ODN immune activator and zinc ions, and standing to obtain the zinc ion polypeptide compound immunologic adjuvant. A dual-adjuvant system mixed with CpG ODN shows excellent performance in activation of lung tissue immunity, and in the cellular immunity level, the response intensity of CD4 + T and CD8 + T cells is enhanced, and formation of related tissue resident memory T cell phenotypes is promoted; on the humoral immunity level, a Gel (Zn < 2 + >) and CpG ODN dual-adjuvant system obviously stimulates the increase of the number of B cells and the activation, and can effectively stimulate the secretion of a main antibody sIgA for mucosal immunity. On the whole, the dual adjuvants realize the synergistic enhancement of T cell (containing TRM) and B cell immunity.

To provide a ligand binding to nectin-4 present on cancer cells, or a pharmaceutically acceptable salt thereof.SOLUTION: The present invention relates to heterotandem bicyclic peptide complexes comprising a first peptide ligand that binds to a component present on a cancer cell conjugated via a linker to a second peptide ligand that binds to a component present on an immune cell. The invention also relates to the use of said heterotandem bicyclic peptide complexes in the prevention, inhibition or treatment of cancer.SELECTED DRAWING: None

The present disclosure relates to multispecific molecules comprising a peptide-MHC complex and an immune cell antigen targeting moiety. Particular embodiments relate to multimeric (e.g., dimeric) molecules comprising a peptide-MHC complex, an immune cell antigen targeting moiety, and a multimerization moiety. The present disclosure further provides pharmaceutical compositions comprising the multispecific molecules, and methods of using the multispecific molecules in antigen-specific T cell activation, in inducing antigen-specific immune responses, and in therapeutic applications, as well as nucleic acids encoding the multispecific molecules, recombinant cells expressing the multispecific molecules, and methods of producing the multispecific molecules.

A peptide complex of the present invention promotes the expression of an SIRT1 gene, which is known as a longevity gene, promotes the expression of an FGF21 gene and increases the phosphorylation of AMPK. In addition, a peptide complex of the present invention exhibits an anti-inflammatory effect. Therefore, the peptide complex of the present invention inhibits aging, promotes the expression of SIRT1 gene, which is a longevity gene, and can be used for treating or preventing SIRT1-related diseases.

The application discloses a nano-drug delivery system containing a stabilizer and a preparation method and application thereof, and belongs to the technical field of medicine preparation. The nano-drug delivery system containing the stabilizer comprises a cationic polypeptide / siRNA complex and a particle size stabilizer; the cationic polypeptide / siRNA complex is formed by non-covalent force between a cationic polypeptide and siRNA, and the amino acid sequence of the cationic polypeptide is KKK(RH4RH4RH4RH4R) x wherein x=3 or 4; and the particle size stabilizer is a surfactant or a protein. Experiments prove that the delivery system combined with the cationic polypeptide and the particle size stabilizer has stable nano size in pure water and biological matrix, and has high gene silencing efficiency at the cell level, and does not significantly reduce the cell transfection or knockout efficiency. Therefore, the nano-drug delivery system can keep nano size in the biological matrix for a long time, and has particle size stability.

The invention relates to a preparation method of a narrow gadus bone peptide compound and chelated calcium of the narrow gadus bone peptide compound. The method comprises the following steps: by taking a walleye cod processing byproduct fish bone as a raw material, carrying out trypsin preliminary enzymolysis, ultrafiltration and protease K targeted enzymolysis to obtain the walleye cod bone peptide compound. The narrow gadus bone peptide compound comprises one or more active peptides of DFF, DIF, DNAF, DPF and DYF. Chelated calcium can be prepared by using the narrow gadus bone peptide compound or the narrow gadus bone active peptide. Waste resources are fully utilized, high value of low-value products is achieved, environmental pollution is reduced, high economic and social benefits are achieved, and the prepared chelated calcium with the high additional value can be applied to the fields of dietary nutrition, biological medicine products and the like.

To provide antigen-binding proteins (ABPs) for use to discover and identify tumor-associated HLA-peptide complexes with highly positive predictive value, and for use in TCR-based immunotherapies targeting such complexes.SOLUTION: The disclosure provides an ABP that binds specifically to an HLA-peptide antigen comprising an HLA-restricted peptide forming a complex with an HLA Class I molecule, where the HLA-restricted peptide is located in the peptide binding groove of an α1 / α2 heterodimer portion of the HLA Class I molecule, where the HLA Class I molecule and the HLA-restricted peptide each have a specific amino acid sequence, and where the ABP comprises a T cell receptor (TCR) or antigen-binding fragment thereof.SELECTED DRAWING: Figure 12

The application belongs to the field of biology, and discloses a method for high-throughput screening of viral CTL epitopes based on immunopeptidomics, which comprises the following steps: transfecting mammalian cells with eukaryotic expression plasmids having MHC I molecules in series with the alpha chain and the beta2m chain to establish a mammalian cell line expressing animal MHC I molecules; using a virus to infect the mammalian cell line expressing MHC I molecules to prepare MHC I-peptide complexes; and obtaining antigen peptides existing in the MHC I-peptide complexes. The method takes chicken MHC I allele BF2*1901 molecules as the research object, takes H9N2 subtype avian influenza virus as the model virus, comprehensively characterizes chicken MHC I restricted H9N2 antigen peptide groups, and identifies immunodominant CTL epitope immunity, and is suitable for CTL epitope screening of different chicken MHC I molecules and different subtypes of avian influenza viruses, provides a fast, efficient and economical technical means for studying the specific binding of chicken MHC I molecules and antigen peptides, provides a favorable reference for T cell epitope screening of major animal pathogens, and provides a scientific basis for poultry disease-resistant breeding, development of new vaccines and immune evaluation strategies. Meanwhile, the application also discloses restricted epitope peptides, nucleic acid molecules and applications.

The invention relates to the technical field of chemical synthesis of medicines, in particular to a peptide compound, a peptide ligand, a peptide complex and application thereof. The peptide compound as well as the peptide ligand and the peptide complex thereof provided by the invention have remarkable uPAR targeting specificity and excellent uPAR affinity, which indicates that the peptide compound, the peptide ligand and the peptide complex can act on related diseases with high uPAR expression, or can be used as carriers to carry nuclides to be accurately delivered to tumor sites, so that the treatment effect is improved. The peptide compounds, the peptide ligands and the peptide complexes have the advantages that uPAR targeting specificity is remarkable, and a novel clinical solution is provided for accurate diagnosis and treatment of uPAR high-expression tumors.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

Heteromultimeric polypeptides comprising a heterodimeric polypeptide complex are provided, as well as methods of production that facilitate the formation of the heterodimeric polypeptide complex. The heterodimer polypeptide complex comprises two combined polypeptide immunoglobulin CH3 domains, wherein each region contains one or more mutations that facilitate heterodimer formation. The heteromultimeric complexes are useful, for example, to promote the production of multispecific binding proteins.

The present invention relates to a peptide conjugate having anti-diabetic activity and uses thereof. The peptide conjugate of the present invention exhibits blood glucose level lowering efficacy by promoting glucose absorption into cells, suppressing insulin resistance signals, promoting insulin sensitivity signals, and suppressing the death of pancreatic β cells, which are insulin-producing cells. The present invention also relates to a peptide having anti-diabetic and anti-obesity activities and uses thereof. The peptide of the present invention has activities of suppressing insulin resistance signals, promoting insulin sensitivity signals, and promoting fat breakdown in adipocytes.

The present application relates to a kind of spent grain protein peptide and its preparation method and application. Specifically, with beer brewing by-product spent grain as raw material, it is prepared by protease enzymolysis to prepare spent grain enzymolysis oligopeptide, and it is proved by mouse in-vivo experiment that the enzymolysis complex has the function of improving blood sugar, obesity, blood fat. On this basis, from the enzymolysis product, the key blood sugar reducing active peptide segment FPQPPQ, FPQQPPFG, FPQPQQPFP is identified, and it is verified that its alpha amylase inhibition rate is superior to the same concentration of acarbose. The spent grain protein peptide complex and spent grain protein peptide of the present application have the effect of reducing blood sugar, and can be applied to the development of food, health food, medicine and the like.

The application discloses an antigen-engineered nanovesicle vaccine (AN-FV) and a preparation method and application thereof. The vaccine is formed by fusion of vesicles of tumor cell membranes obtained by pretreatment of functionalized nanometer preparations and vesicles of mature dendritic cell membranes; the functionalized nanometer preparations contain autophagy inhibiting siRNA and an immunogenicity enhancer, and can synergistically improve MHC-I expression of tumor cells and antigen immunogenicity. The vaccine of the application simultaneously presents high-density MHC-I-antigen peptide complexes and CD80 / CD86 costimulatory molecules on the surface of a single particle, simulates an immune synapse in a nanometer scale, and thus efficiently activates tumor-specific T cells. The vaccine integrates antigen source engineering, physiologicalization of costimulatory signals and nanometer platform integration, and provides a new scheme for overcoming the treatment bottleneck of immune "cold" tumors such as pancreatic cancer.